Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

Next Previous
Trial Profile

An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia; Hypoxaemia; Respiratory insufficiency
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 26 Feb 2022 Results published in the Clinical Infectious Diseases
    • 08 Sep 2021 Results of this post-hoc analyses published in the Journal of Infectious Diseases
    • 16 Jul 2020 Planned End Date changed from 20 Jul 2021 to 31 Aug 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top